Immunotherapy for lymphoid malignancies progressed dramatically in 2017, with FDA approval of two CAR T-cell products, axicabtagene ciloleucel and tisagenlecleucel. In this interview, Yi Lin, MD, PhD, of the Mayo Clinic, Rochester, MN, discusses future clinical trials that are planned for CAR T-cells. Dr Lin highlights the potential of innovative strategies, including utilizing novel technologies, to produce the next generation of CAR T-cells. She also emphasizes the need for and promise of managing CAR T-cell therapy-related toxicities. This video was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.

свернуть